Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course

Size: px
Start display at page:

Download "Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course"

Transcription

1 The American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) through the Approved Continuing Education ACE) program. The American Association for the Treatment of Opioid Dependence (AATOD) maintains responsibility for the program. ASWB Approval Period: 6/12/2013 6/12/2016. Social workers should contact their regulatory board to determine course approval. Social workers participating in this course will receive (clinical or social work ethics) continuing education clock hours. PC1 - Pre-Conference Session Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course Discuss basic information regarding medication assisted treatment developed by the National Alliance for Medication Assisted Treatment (NAMA Recovery). Develop an understanding about the science of addiction Describe the laws behind methadone and buprenorphine treatment Identify basic tools to work as an advocate. Explain how advocacy and the media respond to each other and how to properly handle different situations. Identify ways to use advocacy to change policy. Analyze advocacy campaigns to target an issue or respond to negative and incorrect information about medication assisted treatment. Describe the basic ethics for being an advocate and types of advocacy including handling grievances, systems advocacy, education of policy makers and the community. Credit Hours: 8 PC2 - Pre-Conference Session Title: Buprenorphine and Office-Based Treatment of Opioid Dependence Identify goals of the course and discuss their relevance to opioid dependence. Discuss buprenorphine efficacy and safety. Identify legislative changes.

2 Describe patient selection. Demonstrate clinical use of buprenorphine. Discuss non-pharmacological interventions Discuss medical and psychiatric conditions in opioid dependent patients. Discuss special treatment populations. Demonstrate office procedures. Credit Hours: 8.5 PC3 - Pre-Conference Session Title: Opioid Dependence in Peri-Partum Women: Policy, Collaboration, and Strategy Identify collaborative partnerships necessary in developing a coordinated response between child welfare, substance abuse treatment, medication assisted treatment, family court and medical professionals. To identify promising practices being implemented to improve outcomes for women with opioid dependency and their infants exposed in utero. Describe effective strategies and technical assistance needed by pregnant and postpartum women treatment programs. PC4 - Pre-Conference Session Title: OTP Clinical Staff Education Workshop Define best clinical practice to reduce morbidity and mortality associated with methadone maintenance therapy (MMT) in opioid addiction patients. Identify the risks associated with use of methadone in MMT Describe the unique characteristics of methadone pharmacology and pharmacotherapy. Demonstrate opioid treatment program (OTP) patient screening, assessment, induction, stabilization and maintenance techniques in MMT.

3 Identify and address co-occurring medical/psychiatric disorders that are seen in opioid addicted patients. Design treatment services and levels of care for patients in MMT. Course Target Audience: Beginning & Intermediate Credit Hours: 7 PC5 - Pre-Conference Session Title: Nurses and Opioid Treatment Programs Define Best Practice Guidelines for nurses working in an opioid treatment program setting. Identify key practice recommendations pertaining to nurses role in Medication Assisted Treatment. Identify educational, organizational, and policy recommendations to create a supportive environment for nurses. Course Target Audience: Beginning & Intermediate PC6 - Pre-Conference Session Title: Countering Opioid Stigma: Communicating Messages to Influence Public Perception Explain how negative public opinion and media affect the field and its ability to influence drug policy. Identify key messages designed to counter the stigma and stereotypes in opioid addiction and MAT. Describe effective communication techniques with media representatives about the treatment system.

4 PC7 - Pre-Conference Session Title: New and emerging medications for the treatment of opioid use disorder Describe medications for treating opioid dependence and overdose. Compare and contrast the use of MAT and naltrexone for opioid dependence. Discuss the use of non-opioid medications for the treatment of opioid use disorder and its impact on treatment adherence. PC8 - Pre-Conference Session Title: Opioid Maintenance Pharmacotherapy: A Course for Clinicians Identify interest in the field of Medication Assisted Treatment (MAT) of opioid dependence. Identify best practices in MAT Describe and discuss current challenges and relevant case studies to facilitate understanding of didactic principles. Describe how to deliver safe and effective MAT for patients with opioid dependence. Credit Hours: 8.5 PC9 - Pre-Conference Session Title: Countering Opioid Stigma: Communicating Messages to Influence Public Perception Explain how negative public opinion and media affect the field and its ability to influence drug policy. Identify key messages designed to counter the stigma and stereotypes in opioid addiction and MAT. Describe effective communication techniques with media representatives about the treatment system.

5 PC10 - Pre-Conference Session Title: Intersection of Pain and Addiction: Research and Clinical Practice Describe the neuropsychobiology of pain and explain the need for multidimensional treatment in patients with co-morbid pain and opioid addiction. Identify specific issues related to acute and chronic pain in patients in opioid treatment programs. Identify effective assessment and treatment strategies for patients with co-morbid pain and opioid dependence. PC11 - Pre-Conference Session Title: State Opioid Treatment Authority Meeting Identify federal and state regulatory entities overseeing the use of medication assisted treatment (MAT). Identify best practices in providing oversight of MAT. Describe strategies to improve joint regulatory monitoring of OTPs. Identify strategies to promote joint oversight and compliance with established protocols in medication assisted treatment. Credit Hours: 8

6 PC12 - Pre-Conference Session Title: Opioid Treatment Program Accreditation Town Hall Meeting Identify and discuss new standards, initiatives & tools available through The Joint Commission. Describe how to implement updated or revised Joint Commission accreditation standards and explain how to access new tools & resources available through The Joint Commission. Develop a patient plan for care, treatment & services that is compliant with all related Joint Commission standards. PC13 - Pre-Conference Session Title: Recovery and Medication Assistance Treatment Identify principles that can be applied for individuals using medication in their recovery. Identify key factors in implementing a peer mentoring program. Describe important resources for organizations to access to improve patient care and assist in the recovery process.

7 PC14 - Pre-Conference Session Title: Managing Workplace Risks: Ten Things Employers Need to Known in 2015 to Avoid Workplace Legal Claim Identify employment litigation as it relates to OTPs. Describe how regulatory changes and state and federal case holdings affect the workforce. Describe risk reduction strategies for employers. Identify strategies to promote compliance with established protocols in medication assisted treatment. Course Target Audience: Advanced PC15 - Pre-Conference Session Title: OTP Liability for Patient-Related Motor Vehicle Accidents: A Mock Trial and Focus Group Presentation Identify the risk of opioid treatment programs (OTPs) liability for patients in medication assisted treatment. Develop knowledge about approved policies to treat chronic opioid addiction. Describe current regulations explained by judicial personnel working within the systems. PC16 - Pre-Conference Session Title: Presentation by the World Federation for the Treatment of Opioid Dependence Identify strategies implemented by patients who misuse opiates/opioids while in opioid maintenance treatment. Discuss measurable outcomes in opioid dependence care. Analyze the effects of agonist opioid treatment on sexual dysfunctions.

8 Identify strengths and limitations of replacement therapy method resettlement in prisons. Describe emerging trends in alternative routes for prescription drug misuse in Europe. Describe the utilization of motivational interviewing to facilitate 12 steps for opiate addiction. Explain existing and future treatments and prevention of hepatitis C. Identify factors associated with outcome of inpatient opioid addiction treatment. Identify risk factors for weight gain among patients in methadone maintenance treatment. Discuss the utilization of naloxone in an effort to prevent opioid overdose. Describe effectiveness of medications utilized in the treatment of opioid addiction. Describe the work of the World Federation for the Treatment of Opioid Dependence PC17 - Pre-Conference Session Title: Overdose Prevention Implementation Strategies Describe the significant need for both systemic and individual interventions for healthcare professionals and first responders to address opioid overdoses. Identify current evidence for the administration of naloxone to reverse opioid overdoses by bystanders. Describe steps in the utilization of naloxone to reverse opioid overdose.

Title: Opening Plenary Session Challenges and Opportunities to Impact the Opioid Dependence Crisis

Title: Opening Plenary Session Challenges and Opportunities to Impact the Opioid Dependence Crisis The American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org,

More information

Web-Based Resources. Locating Treatment

Web-Based Resources. Locating Treatment Web-Based Resources Locating Treatment http://dpt2.samhsa.gov/treatment/ -- This is the Substance Abuse and Mental Health Services Administration s (SAMHSA) page for locating both public and private opiate

More information

Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio

Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,

More information

Governor s Task Force on Mental Health and Substance Use. www.ncdhhs.gov/mhsu

Governor s Task Force on Mental Health and Substance Use. www.ncdhhs.gov/mhsu Governor s Task Force on Mental Health and Substance Use www.ncdhhs.gov/mhsu Problem Statement 97 Painkiller prescriptions per 100 North Carolinians Number of deaths by drug overdose in North Carolina

More information

John R. Kasich, Governor Orman Hall, Director

John R. Kasich, Governor Orman Hall, Director John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemic

More information

TREATMENT MODALITIES. May, 2013

TREATMENT MODALITIES. May, 2013 TREATMENT MODALITIES May, 2013 Treatment Modalities New York State Office of Alcoholism and Substance Abuse Services (NYS OASAS) regulates the addiction treatment modalities offered in New York State.

More information

The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section

The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section TITLE I: PREVENTION SUBTITLE A- PRESCRIBER EDUCATION PRACTITIONER EDUCATION This subtitle requires practitioners who

More information

Medication treatments for opioid use disorders

Medication treatments for opioid use disorders Medication treatments for opioid use disorders Summary for counties JUDITH MARTIN, Medical Director of Substance Use Services, San Francisco Department of Public Health Brief history of Methadone and Buprenorphine

More information

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines

More information

Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015

Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015 Q: I have read 40 mg of methadone stops withdrawal, so why don t we start at 30mg and maybe later in the day add 10mg? A: Federal Regulations stipulate that 30mg is the maximum first dose in an Opioid

More information

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act IN THE GENERAL ASSEMBLY STATE OF Ensuring Access to Medication Assisted Treatment Act 1 Be it enacted by the People of the State of Assembly:, represented in the General 1 1 1 1 Section 1. Title. This

More information

Objectives: Perform thorough assessment, and design and implement care plans on 12 or more seriously mentally ill addicted persons.

Objectives: Perform thorough assessment, and design and implement care plans on 12 or more seriously mentally ill addicted persons. Addiction Psychiatry Program Site Specific Goals and Objectives Addiction Psychiatry (ADTU) Goal: By the end of the rotation fellow will acquire the knowledge, skills and attitudes required to recognize

More information

Treatment of opioid use disorders

Treatment of opioid use disorders Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence

More information

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA

More information

Testimony of The New York City Department of Health and Mental Hygiene. before the

Testimony of The New York City Department of Health and Mental Hygiene. before the Testimony of The New York City Department of Health and Mental Hygiene before the New York City State Assembly Committee on Alcoholism and Drug Abuse on Programs and Services for the Treatment of Opioid

More information

U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health

U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health TESTIMONY of the American Medical Association before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health Re: Examining Legislative Proposals to Combat our Nation's

More information

EPIDEMIOLOGY OF OPIATE USE

EPIDEMIOLOGY OF OPIATE USE Opiate Dependence EPIDEMIOLOGY OF OPIATE USE Difficult to estimate true extent of opiate dependence Based on National Survey of Health and Mental Well Being: 1.2% sample used opiates in last 12 months

More information

Prescriber Behavior, Pain Treatment and Addiction Treatment

Prescriber Behavior, Pain Treatment and Addiction Treatment Prescriber Behavior, Pain Treatment and Addiction Treatment Mary Fleming, M.S. Director, Office of Policy, Planning, and Innovation Substance Abuse and Mental Health Services Administration NGA Policy

More information

National Perspectives in Medication Assisted Treatment

National Perspectives in Medication Assisted Treatment National Perspectives in Medication Assisted Treatment Addiction Medicine Asheville March 21,2014 Melinda Campopiano, MD Medical Officer Substance Abuse & Mental Health Services Administration Guten Appetit

More information

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment: Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society

More information

American Society of Addiction Medicine

American Society of Addiction Medicine American Society of Addiction Medicine Public Policy Statement on Office-based Opioid Agonist Treatment (OBOT) BACKGROUND Methadone maintenance treatment of opioid addiction was developed in 1965 and implemented

More information

Addressing Substance Abuse in the Child Welfare Population: Lessons Learned in Vermont

Addressing Substance Abuse in the Child Welfare Population: Lessons Learned in Vermont Agency of Human Services Alcohol and Drug Abuse Programs Blueprint for Health Addressing Substance Abuse in the Child Welfare Population: Lessons Learned in Vermont Tri-Branch Institute on Child Social

More information

Alcohol and Drug Abuse Treatment Centers

Alcohol and Drug Abuse Treatment Centers Division of State Operated Healthcare Facilities Alcohol and Drug Abuse Treatment Centers Jenny Wood Interim ADATC Team Leader HHS LOC Mental Health Subcommittee February 24, 2014 ADATC Locations R.J.

More information

Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians

Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse

More information

Confronting the Crisis of Opioid Addiction: An Overview of Beacon s White Paper

Confronting the Crisis of Opioid Addiction: An Overview of Beacon s White Paper Confronting the Crisis of Opioid Addiction: An Overview of Beacon s White Paper July 2, 2015 B. Steven Bentsen MD, DFAPA Board certified in Addiction Medicine Opioid Addiction Is Headline News Why? There

More information

STATE PLAN TO PREVENT AND TREAT PRESCRIPTION DRUG ABUSE RECOMMENDATION SUMMARY Governor s Prescription Drug Abuse Prevention Council

STATE PLAN TO PREVENT AND TREAT PRESCRIPTION DRUG ABUSE RECOMMENDATION SUMMARY Governor s Prescription Drug Abuse Prevention Council STATE PLAN TO PREVENT AND TREAT PRESCRIPTION DRUG ABUSE RECOMMENDATION SUMMARY Governor s Prescription Drug Abuse Prevention Council PRIORITY AREA: PRESCRIBERS Recommendation: The Council recommends that

More information

Acronyms for the Prevention and Treatment of Substance Use Disorders. Prepared by Mental Health Legal Advisors Committee November 2015

Acronyms for the Prevention and Treatment of Substance Use Disorders. Prepared by Mental Health Legal Advisors Committee November 2015 s for the Prevention and Treatment of Substance Use Disorders Prepared by Mental Health Legal Advisors Committee November 2015 Acro ABH ACA A- CRA ACC Association A statewide association ABH of Behavioral

More information

Lazarus Recovery Services

Lazarus Recovery Services Lazarus Recovery Services Overdose Survivors Group Family Addiction Support Family Peer Specialist Support Housing Family Overdose Support Biological Psychological Parent/ Family Empowerment Faith Individual

More information

Findings and Recommendations

Findings and Recommendations 6 Findings and Recommendations The committee s review of current research, models for collaboration between research and practice, community-based organizations, and dissemination strategies led to findings

More information

Care Management Council submission date: August 2013. Contact Information

Care Management Council submission date: August 2013. Contact Information Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing

More information

Addiction Psychiatry Fellowship Rotation Goals & Objectives

Addiction Psychiatry Fellowship Rotation Goals & Objectives Addiction Psychiatry Fellowship Rotation Goals & Objectives Table of Contents University Neuropsychiatric Institute (UNI) Training Site 2 Inpatient addiction psychiatry rotation.....2 Outpatient addiction

More information

How To Treat Anorexic Addiction With Medication Assisted Treatment

How To Treat Anorexic Addiction With Medication Assisted Treatment Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious

More information

Performance Standards

Performance Standards Performance Standards Co-Occurring Disorder Competency Performance Standards are intended to provide a foundation and serve as a tool to promote continuous quality improvement and progression toward best

More information

Statement. of the. American Medical Association. to the

Statement. of the. American Medical Association. to the Statement of the American Medical Association to the Committee on Energy & Commerce Subcommittee on Oversight and Investigations United States House of Representatives Re: Combatting the Opioid Abuse Epidemic:

More information

Buprenorphine Therapy in Addiction Treatment

Buprenorphine Therapy in Addiction Treatment Buprenorphine Therapy in Addiction Treatment Ken Roy, MD, FASAM Addiction Recovery Resources, Inc. River Oaks Hospital Tulane Department of Psychiatry www.arrno.org Like Minded Doc What is MAT? Definition

More information

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Sidarth Wakhlu,M.D. Addiction Team Leader North Texas VA Health Care System Addiction Psychiatry Fellowship Director Associate Professor Of Psychiatry

More information

Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism

Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism Richard A. Rawson, Ph.D, Professor Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine University

More information

HOPE Helping Opiate- Addicted Pregnant women Evolve

HOPE Helping Opiate- Addicted Pregnant women Evolve HOPE Helping Opiate- Addicted Pregnant women Evolve Medical Director: Michael P. Marcotte, MD TriHealth-Good Samaritan Hospital Cincinnati Ohio MHAS MOMs Grant 2014-2016 Ohio MHAS MOMs Grant 2014-2016

More information

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,

More information

Professional Intervention and Treatment Related to Opioid Misuse and Addiction

Professional Intervention and Treatment Related to Opioid Misuse and Addiction Professional Intervention and Treatment Related to Opioid Misuse and Addiction Michael M. Miller, MD, FASAM, FAPA Drug Poisoning Summit: Stop the Overdose Epidemic January 30, 2012 University of Wisconsin

More information

Non medical use of prescription medicines existing WHO advice

Non medical use of prescription medicines existing WHO advice Non medical use of prescription medicines existing WHO advice Nicolas Clark Management of Substance Abuse Team WHO, Geneva Vienna, June 2010 clarkn@who.int Medical and Pharmaceutical role Recommendations

More information

Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to

Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to 2012 Page 1 of 8 1 2 3 4 5 H.627 Introduced by Representative Pugh of South Burlington Referred to Committee on Date: Subject: Health; food and drugs; treatment of opiate addiction Statement of purpose:

More information

Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas

Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas David Lakey, MD Commissioner, Department of State Health Services Lauren Lacefield Lewis Assistant Commissioner,

More information

Alcohol and Drug. A Cochrane Handbook. losief Abraha MD. Cristina Cusi MD. Regional Health Perugia

Alcohol and Drug. A Cochrane Handbook. losief Abraha MD. Cristina Cusi MD. Regional Health Perugia Alcohol and Drug A Cochrane Handbook losief Abraha MD Regional Health Perugia of Cristina Cusi MD Outpatient Services - Neurology Clinical Institutes of Specialisation Milan Italy A John Sons, Ltd., THE

More information

FISCAL IMPACT STATEMENT. LS 7351 NOTE PREPARED: Feb 6, 2015 BILL NUMBER: SB 464 BILL AMENDED: Feb 5, 2015

FISCAL IMPACT STATEMENT. LS 7351 NOTE PREPARED: Feb 6, 2015 BILL NUMBER: SB 464 BILL AMENDED: Feb 5, 2015 LEGISLATIVE SERVICES AGENCY OFFICE OF FISCAL AND MANAGEMENT ANALYSIS 200 W. Washington, Suite 301 Indianapolis, IN 46204 (317) 233-0696 http://www.in.gov/legislative FISCAL IMPACT STATEMENT LS 7351 NOTE

More information

S. ll. To provide access to medication-assisted therapy, and for other purposes. IN THE SENATE OF THE UNITED STATES A BILL

S. ll. To provide access to medication-assisted therapy, and for other purposes. IN THE SENATE OF THE UNITED STATES A BILL ALB TH CONGRESS D SESSION S. ll To provide access to medication-assisted therapy, and for other purposes. IN THE SENATE OF THE UNITED STATES llllllllll Mr. MARKEY (for himself, Mrs. FEINSTEIN, Mr. ROCKEFELLER,

More information

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by

More information

Opioid Treatment Services, Office-Based Opioid Treatment

Opioid Treatment Services, Office-Based Opioid Treatment Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,

More information

Licensure of Substance Abuse Treatment Programs Required Amendments

Licensure of Substance Abuse Treatment Programs Required Amendments Licensure of Substance Abuse Treatment Programs Required Amendments Public Health Council August 12, 2015 Jim Cremer, Deputy Director Erica Piedade, Director of Quality Assurance & Licensing, Overview

More information

Resources for the Prevention and Treatment of Substance Use Disorders

Resources for the Prevention and Treatment of Substance Use Disorders Resources for the Prevention and Treatment of Substance Use Disorders Table of Contents Age-standardized DALYs, alcohol and drug use disorders, per 100 000 Age-standardized death rates, alcohol and drug

More information

1) What would it take to get four or five FQHCs to implement ECHO, and how many patients can we serve?

1) What would it take to get four or five FQHCs to implement ECHO, and how many patients can we serve? RI Mental Health Summit Lightning Round Q&A s June 8, 2015 Opiate Addiction Epidemic 1) What would it take to get four or five FQHCs to implement ECHO, and how many patients can we serve? 2) What would

More information

Office-based Treatment of Opioid Dependence with Buprenorphine

Office-based Treatment of Opioid Dependence with Buprenorphine Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures

More information

Opioid/Opiate Dependent Pregnant Women

Opioid/Opiate Dependent Pregnant Women Opioid/Opiate Dependent Pregnant Women The epidemic, safety, stigma, and how to help. Presented by Lisa Ramirez MA,LCDC & Kerby Stewart MD The prescription painkiller epidemic is killing more women than

More information

Opioid Addiction & Corrections

Opioid Addiction & Corrections Opioid Addiction & Corrections Medication Assisted Treatment in the Connecticut Department of Correction April 30, 2015--CJPAC Kathleen F. Maurer, MD, MPH, MBA Medical Director and Director of Health and

More information

Increasing Access to Opioid Addiction Treatment

Increasing Access to Opioid Addiction Treatment Report to The Vermont Legislature Increasing Access to Opioid Addiction Treatment In Accordance with Act 75, 2013, Section 14b An Act Relating to Strengthening Vermont s Response to Opioid Addiction and

More information

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK National Institute on Drug Abuse SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK U.S. Department of Health and Human National Institutes of Health SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK The goal

More information

Bsafe Blackpool Community Safety and Drugs Partnership. Drug and Alcohol treatment planning in the community for Young People and Adults 2012/13

Bsafe Blackpool Community Safety and Drugs Partnership. Drug and Alcohol treatment planning in the community for Young People and Adults 2012/13 Bsafe Blackpool Community Safety and Drugs Partnership Drug and Alcohol treatment planning in the community for Young People and Adults 2012/13 Planning Framework Treatment plan Planning Framework Bsafe

More information

Travis Baggett, MD, MPH Jessie M. Gaeta, MD Jennifer Brody, MD, MPH Boston Health Care for the Homeless Program

Travis Baggett, MD, MPH Jessie M. Gaeta, MD Jennifer Brody, MD, MPH Boston Health Care for the Homeless Program Travis Baggett, MD, MPH Jessie M. Gaeta, MD Jennifer Brody, MD, MPH Boston Health Care for the Homeless Program Substance- attributable mortality Presentation of the data Implications for our model of

More information

State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff

State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff Funding Source: Grant No. 053773 Robert Wood Johnson Foundation Substance Abuse Policy Research

More information

Joel Millard, DSW, LCSW Dave Felt, LCSW

Joel Millard, DSW, LCSW Dave Felt, LCSW Joel Millard, DSW, LCSW Dave Felt, LCSW 1. Provide an overview of the effectiveness of medication assisted treatment, to include a discussion of the different types of medications and how they are used

More information

Opioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist

Opioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist Opioid Addiction and Methadone: Myths and Misconceptions Nicole Nakatsu WRHA Practice Development Pharmacist Learning Objectives By the end of this presentation you should be able to: Understand how opioids

More information

MAT Counselor Education Course Exam Questions Packet Part 1

MAT Counselor Education Course Exam Questions Packet Part 1 MAT Counselor Education Course Exam Questions Packet Part 1 Course No: Course Title: Course Objective: MA-1901P1 Medication-Assisted Treatment (MAT) Counselor Education Course Part 1 Includes primer on

More information

An integrated approach to addressing opiate abuse in Maine. Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009

An integrated approach to addressing opiate abuse in Maine. Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009 An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009 Background Defining the problem: Opiates pain relievers (OxyContin,

More information

Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended. (1) by striking clause (ii) and inserting the following:

Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended. (1) by striking clause (ii) and inserting the following: Section XX. Definitions. Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended (1) by striking clause (ii) and inserting the following: (ii) The term qualifying practitioner

More information

Use of Pharmacotherapies by Substance Abuse Treatment Facilities

Use of Pharmacotherapies by Substance Abuse Treatment Facilities Use of Pharmacotherapies by Substance Abuse Treatment Facilities Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration Department of Health and Human Services November 2007 1

More information

Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office

Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office Vermont Board of Medical Practice Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office Background and Introduction The Vermont Board of Medical Practice (the Board) is committed

More information

Role of Medication in the Treatment of Opioid Use Disorders

Role of Medication in the Treatment of Opioid Use Disorders Role of Medication in the Treatment of Opioid Use Disorders Carolyn Baird, DNP, MBA, RN-BC, CARN-AP, CCDPD, FIAAN International Nurses Society on Addictions (IntNSA) August 24, 2015 Disclosures Carolyn

More information

The Need for Medication-Assisted Treatment (MAT)

The Need for Medication-Assisted Treatment (MAT) Presenters Erin Hall MSOT Hon. Kyle B. Haskins Closed Doors or Welcome Mat? Opening the Way for Medication-Assisted Treatment in Family Drug Courts Oklahoma Specialty Court Conference Thursday September

More information

The Use of Non-Opioid Pharmacotherapies. for the Treatment of Alcohol Dependence

The Use of Non-Opioid Pharmacotherapies. for the Treatment of Alcohol Dependence M00K02 Alcohol and Drug Abuse Administration Department of Health and Mental Hygiene The Use of Non-Opioid Pharmacotherapies for the Treatment of Alcohol Dependence Introduction The 2011 Joint Chairmen

More information

RULES OF THE ALABAMA BOARD OF MEDICAL EXAMINERS

RULES OF THE ALABAMA BOARD OF MEDICAL EXAMINERS RULES OF THE ALABAMA BOARD OF MEDICAL EXAMINERS CHAPTER 540-X-21 POLICY ON DATA 2000: GUIDELINES FOR THE TREATMENT OF OPIOID ADDICTION IN THE MEDICAL OFFICE 1 Table of Contents 540-X-21-.01 Introduction

More information

Treatment of Opioid Use Disorders in Jails and Prisons Why, When, and How

Treatment of Opioid Use Disorders in Jails and Prisons Why, When, and How Treatment of Opioid Use Disorders in Jails and Prisons Why, When, and How Kevin Fiscella, MD, MPH Professor, Family Medicine, Public Health Sciences, Community Health University of Rochester School of

More information

Reforming the Response To Substance Use: A Drug Policy for the 21 st Century

Reforming the Response To Substance Use: A Drug Policy for the 21 st Century Reforming the Response To Substance Use: A Drug Policy for the 21 st Century 2015 NASADAD MEETING Charleston, SC June 2, 2015 David Mineta, Deputy Director Office of Demand Reduction Office of National

More information

Washington State Interagency Opioid Working Plan

Washington State Interagency Opioid Working Plan Washington State Interagency Opioid Working Plan INTRODUCTION January 2016 Washington State is currently experiencing an opioid abuse and overdose crisis involving prescription opioids and heroin. Approximately

More information

The Heroin and Opioid Epidemic in Northeast Ohio: One Year Report to the Community

The Heroin and Opioid Epidemic in Northeast Ohio: One Year Report to the Community The Heroin and Opioid Epidemic in Northeast Ohio: One Year Report to the Community The Heroin and Opioid Epidemic in Northeast Ohio: One Year Report to the Community November 2014 INTRODUCTION The Heroin

More information

The Changing Face of Opioid Addiction:

The Changing Face of Opioid Addiction: 9th Annual Training and Educational Symposium September 6, 2012 The Changing Face of Opioid Addiction: A Review of the Research and Considerations for Care Mark Stanford, Ph.D. Santa Clara County Dept

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)

More information

Various therapies are used in the

Various therapies are used in the National Survey of Substance Abuse Treatment Services The N-SSATS Report January 28, 2010 Overview of Opioid Treatment Programs within the United States: 2008 In Brief In 2008, a total of 1,132 (8 of all

More information

Medication Assisted Treatment

Medication Assisted Treatment Medication Assisted Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority Bureau Of Prevention, Treatment, & Recovery State of Wisconsin Elizabeth Collier, MSW, CSAC, ICS, LCSW TANF Best Practice

More information

A Drug Policy for the 21st Century. Office of National Drug Control Policy

A Drug Policy for the 21st Century. Office of National Drug Control Policy A Drug Policy for the 21st Century October 18, 2014 International Nurses Society on Addictions Health Care Reform & Its Impact on Addictions Nursing: Navigating Change through the Rapids David K. Mineta,

More information

Confronting the Crisis of Opioid Addiction: An Overview of Beacon s White Paper

Confronting the Crisis of Opioid Addiction: An Overview of Beacon s White Paper Confronting the Crisis of Opioid Addiction: An Overview of Beacon s White Paper August 2015 Introduction Agenda Brief introduction to Beacon and our speakers Overview of Beacon s White Paper in response

More information

Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to

Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to 2012 Page 1 of 6 1 2 3 4 5 H.627 Introduced by Representative Pugh of South Burlington Referred to Committee on Date: Subject: Health; food and drugs; treatment of opiate addiction Statement of purpose:

More information

MEDICAL POLICY Treatment of Opioid Dependence

MEDICAL POLICY Treatment of Opioid Dependence POLICY........ PG-0313 EFFECTIVE......11/11/14 LAST REVIEW... 07/14/15 MEDICAL POLICY Treatment of Opioid Dependence GUIDELINES This policy does not certify benefits or authorization of benefits, which

More information

ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE

ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE Medical Examiners Chapter 540-X-21 ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE CHAPTER 540-X-21 POLICY ON DATA 2000: GUIDELINES FOR THE TREATMENT OF OPIOID ADDICTION IN THE MEDICAL OFFICE 1

More information

ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15

ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15 ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;/13;06/14;07/15 WRITTEN BY Jim Johnson Page 1 REVISED BY AUTHORIZED BY Jessica Moeller Debra Johnson I. APPLICATION: THUMB

More information

Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts

Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts Educational Objectives: Review epidemiology of opioid addiction in

More information

Prescription Drug Abuse: Recognition, Intervention, and Prevention

Prescription Drug Abuse: Recognition, Intervention, and Prevention Prescription Drug Abuse: Recognition, Intervention, and Prevention Nicholas Reuter Division of Pharmacologic Therapy Center for Substance Abuse Treatment Substance Abuse and Mental Health Services Administration

More information

Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem. Thomas Kosten MD

Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem. Thomas Kosten MD Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem Thomas Kosten MD Waggoner Chair & Professor of Psychiatry & Neuroscience Baylor College of Medicine Past-President,

More information

Florida Alcohol and Drug Abuse Association. Presented to the Behavioral Health Quarterly Meeting Pensacola, Florida April 23, 2014

Florida Alcohol and Drug Abuse Association. Presented to the Behavioral Health Quarterly Meeting Pensacola, Florida April 23, 2014 Florida Alcohol and Drug Abuse Association Presented to the Behavioral Health Quarterly Meeting Pensacola, Florida April 23, 2014 Florida Alcohol and Drug Abuse Association Founded in 1981 Currently has

More information

Traci C. Green, PhD, MSc Jody Rich, MD, MPH

Traci C. Green, PhD, MSc Jody Rich, MD, MPH Traci C. Green, PhD, MSc Jody Rich, MD, MPH Strategic Plan highlights Comments & Responses from public, stakeholders Input and discussion Next steps Death rate for U.S. non-hispanic whites (USW), U.S.

More information

Presentation to the Boston HIV Planning Council. Lydie Ultimo, MSW Director Bureau of Substance Abuse Services

Presentation to the Boston HIV Planning Council. Lydie Ultimo, MSW Director Bureau of Substance Abuse Services Presentation to the Boston HIV Planning Council Lydie Ultimo, MSW Director Bureau of Substance Abuse Services Responsibilities of the Bureau of Substance Abuse Services License addiction treatment programs

More information

Financial Disclosures

Financial Disclosures Opioid Agonist Therapy: To Maintain or Not To Maintain - A Case Discussion PCSS-MAT American Psychiatric Association Drs. Ed Salsitz, John Renner, Timothy Fong April 14, 2015 Financial Disclosures Edwin

More information

Behavioral Health Provider Implementation of Whole Health Integrative Treatment Services

Behavioral Health Provider Implementation of Whole Health Integrative Treatment Services Behavioral Health Provider Implementation of Whole Health Integrative Treatment Services Maryland Integrative Learning Community Lynn H Albizo, Director of Public Affairs Maryland Addictions Directors

More information

Impact of Systematic Review on Health Services: The US Experience

Impact of Systematic Review on Health Services: The US Experience Impact of Systematic Review on Health Services: The US Experience Walter Ling MD Integrated Substance Abuse Programs (ISAP) UCLA The effectiveness of interventions for addictions: The Drug and Alcohol

More information

BUPRENORPHINE TREATMENT

BUPRENORPHINE TREATMENT BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment Act of 2000 (DATA 2000) Developed by Mountain West

More information

Opioids for Pain Treatment. Opioids for Chronic Pain and Addiction Treatment. Outline for Today. Opioids for pain treatment

Opioids for Pain Treatment. Opioids for Chronic Pain and Addiction Treatment. Outline for Today. Opioids for pain treatment Opioids for Chronic Pain and Addiction Treatment Joseph Merrill M.D., M.P.H. University of Washington February 24, 2012 Outline for Today Opioids for pain treatment Trends Problems High dose prescribing

More information

Development of the guidelines on the pharmacotherapy of addiction case study Croatia

Development of the guidelines on the pharmacotherapy of addiction case study Croatia Development of the guidelines on the pharmacotherapy of addiction case study Croatia Croatia Marina Kuzman Dragica Katalinic Croatian National Institute of Public Health Cyprus, 2009. Drug use and drug

More information

Ohio Legislative Service Commission

Ohio Legislative Service Commission Ohio Legislative Service Commission Bill Analysis Brian D. Malachowsky H.B. 378 130th General Assembly () Reps. Smith and Sprague BILL SUMMARY Prohibits a physician from prescribing or personally furnishing

More information

Update on Buprenorphine: Induction and Ongoing Care

Update on Buprenorphine: Induction and Ongoing Care Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference

More information

The Professional Practice Committee Douglas E. Lentivech. September 8, 2015 SUMMARY

The Professional Practice Committee Douglas E. Lentivech. September 8, 2015 SUMMARY THE STATE EDUCATION DEPARTMENT / THE UNIVERSITY OF THE STATE OF NEW YORK / ALBANY, NY 12234 TO: FROM: SUBJECT: DATE: The Professional Practice Committee Douglas E. Lentivech Proposed Amendment to Section

More information

SUPPORTING WOMEN USING OPIATES IN PREGNANCY: A Guideline for Primary Care Providers May, 2011

SUPPORTING WOMEN USING OPIATES IN PREGNANCY: A Guideline for Primary Care Providers May, 2011 INTRODUCTION SUPPORTING WOMEN USING OPIATES IN PREGNANCY: A Guideline for Primary Care Providers May, 2011 Prevalence of Opiate Use and Impact on Maternal, Fetal, and Neonatal Health: The prevalence of

More information